A randomized study to evaluate virologic response following discontinuation vs. no discontinuation of 3TC [lamivudine] in patients who are infected with HIV with previously documented reduced susceptibility to 3TC and who have adequate virologic suppression on combination antiretroviral therapy

Trial Profile

A randomized study to evaluate virologic response following discontinuation vs. no discontinuation of 3TC [lamivudine] in patients who are infected with HIV with previously documented reduced susceptibility to 3TC and who have adequate virologic suppression on combination antiretroviral therapy

Suspended
Phase of Trial: Phase IV

Latest Information Update: 08 May 2013

At a glance

  • Drugs Lamivudine (Primary) ; Antiretrovirals
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Sep 2008 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.
    • 24 Sep 2008 Planned end date identified as May 2010, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top